A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2002
12/19/2002	US20020192728 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore
12/19/2002	US20020192695 Detection of modulator of tumor suppressor activity; obtain sample of polypeptide, incubate with modulator, monitor adjustment in polypeptide activity
12/19/2002	US20020192682 Polynucleotides and polypeptides of the IFNalpha-2 gene
12/19/2002	US20020192647 Diagnostic method
12/19/2002	US20020192644 Detection of natural killer receptor; obtain samples, incubate with oligonucleotides, detect bound complexes, presence of complexes indicates receptor
12/19/2002	US20020192643 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferation or inflammatory disorders
12/19/2002	US20020192638 Evaluation of cells sensitvity to anticancer agents; obtain tissue, separate, culture tissue, inoculate cells, incubate with anticancer agent, monitor sensitivity to anticancer agents
12/19/2002	US20020192310 Medical composition for managing hormone balance
12/19/2002	US20020192308 Method and composition for controlling weight
12/19/2002	US20020192306 Gastric acid secretion
12/19/2002	US20020192304 Pharmaceutical composition and method for relieving itch, pain and swelling resulting from insect bites and stings
12/19/2002	US20020192288 Methods and compositions for treating pain of the mucous membrane
12/19/2002	US20020192280 Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
12/19/2002	US20020192279 Method for producing antibiotic composites
12/19/2002	US20020192276 Use of G class immunoglobulins for the topical treatment of atopic dermatitis
12/19/2002	US20020192264 Materials and methods for the treatment or prevention of obesity
12/19/2002	US20020192240 Therapy for injured muscles
12/19/2002	US20020192228 Protein markers for lung cancer and use thereof
12/19/2002	US20020192216 Therapeutic use
12/19/2002	US20020192207 Pharmaceutical compositions of fibrinolytic agent
12/19/2002	US20020192203 Sterol absorption inhibitor compositions
12/19/2002	US20020192193 Antigen presenting cells, a process for preparing the same and their use as cellular vaccines
12/19/2002	US20020192192 Antigen presenting cells, a process for preparing the same and their use as cellular vaccines
12/19/2002	US20020192157 Treatment and diagnosis of macrophage mediated disease
12/19/2002	DE10128331A1 New 2-(heteroarylsulfonyl-amino)-benzamide derivatives, which are potassium ion channel blocking antiarrhythmic agents, useful for e.g. treating atrial fibrillation or flutter
12/19/2002	DE10127712A1 Use of immunoglobulin M for treatment and prevention of systemic lupus erythematosus, administered subcutaneously or intramuscularly
12/19/2002	DE10121003A1 Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen Anthranilic acid amides, processes for preparing, their use as a medicament as well as pharmaceutical compositions containing them
12/19/2002	CA2487039A1 Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
12/19/2002	CA2487038A1 Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
12/19/2002	CA2450720A1 In vivo bioreactors
12/19/2002	CA2450379A1 Molecular signatures of commonly fatal carcinomas
12/19/2002	CA2450366A1 Controlled heat induced rapid delivery of pharmaceuticals from skin depot
12/19/2002	CA2450316A1 Cd10-activated prodrug compounds
12/19/2002	CA2450285A1 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
12/19/2002	CA2450269A1 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
12/19/2002	CA2450265A1 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
12/19/2002	CA2450131A1 Respiratory syncytial virus
12/19/2002	CA2450113A1 Vanilloid receptor-related nucleic acids and polypeptides
12/19/2002	CA2450027A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449987A1 Treatment of central neuropathic pain
12/19/2002	CA2449948A1 Methods of treating alzheimer's disease
12/19/2002	CA2449934A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449732A1 Porous sponge-like cellulosic material for treatment of injuries
12/19/2002	CA2449687A1 Vascular regeneration therapy
12/19/2002	CA2449673A1 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
12/19/2002	CA2449654A1 Methods for treating disorders of the nervous and reproductive systems
12/19/2002	CA2449649A1 A g-protein coupled receptor and uses therefor
12/19/2002	CA2449517A1 Tissue-specific endothelial membrane proteins
12/19/2002	CA2449440A1 Structural and cytoskeleton-associated proteins
12/19/2002	CA2449272A1 Intracellular signaling molecules
12/19/2002	CA2449256A1 Modulators of peroxisome proliferator activated receptors
12/19/2002	CA2449249A1 Nr2b receptor antagonists for the treatment or prevention of migraines
12/19/2002	CA2449247A1 A method for treating inflammatory diseases by administering a ppar-delta agonist
12/19/2002	CA2448552A1 Modulators of peroxisome proliferator activated receptors (ppar)
12/19/2002	CA2445605A1 Treatment or prophylaxis of insulin-producing cell graft rejection
12/18/2002	EP1267171A1 Cofactor-based screening method for nuclear receptor modulators
12/18/2002	EP1266227A1 Synergistic activation of regulatory elements by rel proteins and a steroid receptor
12/18/2002	EP1266224A1 Modulation of histone deacetylase
12/18/2002	EP1266208A1 Method of screening compounds for biological activity
12/18/2002	EP1266039A1 Method and kit for the screening, the detection and/or the quantification of transcriptional factors
12/18/2002	EP1266029A1 Diagnosis of a person's risk of developing alcoholism
12/18/2002	EP1266026A1 Modulation of pleiotrophin signaling by receptor-type protein tyrosine phosphatase beta/zeta
12/18/2002	EP1266013A2 Heparinase iii and uses thereof
12/18/2002	EP1266012A2 Proteases
12/18/2002	EP1266009A2 ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF
12/18/2002	EP1266008A2 Acute neuronal induced calcium binding protein type 1 ligand
12/18/2002	EP1266003A2 Kcnb: a potassium channel protein
12/18/2002	EP1266001A2 Human transcription factors
12/18/2002	EP1266000A1 Chordin-like-2 molecules and uses thereof
12/18/2002	EP1265999A2 Human schizophrenia gene
12/18/2002	EP1265996A2 Identification of modulators of the interferon gamma signaling pathway and their use in restenosis treatment
12/18/2002	EP1265995A2 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
12/18/2002	EP1265989A2 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
12/18/2002	EP1265985A1 Pancreatic islet cell growth factors
12/18/2002	EP1265927A1 Crystal
12/18/2002	EP1265924A2 Il-17 receptor like molecules and uses thereof
12/18/2002	EP1265922A2 Agonists and antagonists of the receptor gpr19 and their use in appetite control
12/18/2002	EP1265920A2 Angiogenesis-associated proteins, and nucleic acids encoding the same
12/18/2002	EP1265919A2 G-protein associated molecules
12/18/2002	EP1265918A1 Human immune response proteins
12/18/2002	EP1265915A2 Novel compounds
12/18/2002	EP1265914A2 Wnt-1 related polypeptides, and nucleic acids encoding the same
12/18/2002	EP1265913A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
12/18/2002	EP1265879A1 Allomorph isomer z hydrochloride of ranitidine
12/18/2002	EP1265639A1 The use of anticoagulant agents in the extracorporeal treatment of blood
12/18/2002	EP1265637A2 Compositions and methods for affecting osteogenesis
12/18/2002	EP1265636A2 Improved treatment of neovascularization
12/18/2002	EP1265635A1 Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
12/18/2002	EP1265630A2 Use of insulin for the treatment of cartilagenous disorders
12/18/2002	EP1265628A1 Use of human not1 and not1a orphan receptors
12/18/2002	EP1265627A2 Methods and compositions for inhibiting angiogenesis
12/18/2002	EP1265615A2 Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
12/18/2002	EP1265607A2 METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS
12/18/2002	EP1265602A2 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries
12/18/2002	EP1265598A1 Pharmaceutical composition for application to mucosal surfaces
12/18/2002	EP0989847B1 Anti-tumoral therapy agent
12/18/2002	EP0948349B1 in vitro methods and use of pharmaceutical compositions for the TREATMENT OF INNER EAR HAIR CELLS
12/18/2002	EP0946721B1 Human growth gene and short stature gene region
12/18/2002	EP0873309B1 3-spiro-indolin-2-one derivatives as vasopressin and/or oxytocin receptor ligands
12/18/2002	EP0736002B9 Compound capable of introducing at least one molecule into a cell

1 ... 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 ... 1151